Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats

British Journal of Nutrition

Volumn 99, Issue 4, 2008, Pages 806-812

  Sridhar, M G ^a   Vinayagamoorthi, R ^a   Arul Suyambunathan, V ^a   Bobby, Z ^a   Selvaraj, N ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Bitter gourd; Hyperinsulinaemia; Insulin sensitivity; Insulin signalling; Obesity

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MOMORDICA CHARANTIA EXTRACT; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY FAT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG MECHANISM; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MORNING DOSAGE; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; BODY WEIGHT; CHOLESTEROL; DIET; DIETARY FATS; DIETARY SUPPLEMENTS; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; MALE; MOMORDICA CHARANTIA; MUSCLE PROTEINS; MUSCLE, SKELETAL; PHOSPHORYLATION; RATS; RATS, WISTAR; TRIGLYCERIDES; TYROSINE;

MOMORDICA CHARANTIA; RATTUS; RATTUS NORVEGICUS;

EID: 40449117390     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711450783176X     Document Type: Article

References (42)

1. Saltiel AR & Pessin JE (2002) Insulin signalling pathways in time and space. Trends in Cell Biol 12, 65-71.
2. Pessin JE & Saltiel AR (2000) Signalling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 106, 165-169.
3. Shulman GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106, 171-176.
4. Sathishseker D & Subramanian S (2005) Antioxidant properties of Momordica charantia (bitter gourd) seeds on streptozotocin induced diabetic rats. Asia Pac J Clin Nutr 14(2), 153-158.
5. Grover JK & Yadav SP (2004) Pharmacological actions and potential uses of Momordica charantia: A review. J Ethnopharmacol 93, 123-132.
6. Yibchok-Anun S, Adisakwattana S, Yao CY, Sangvanich P, Roengsumran S & Hsu WH (2006) Slow acting protein extract from fruit pulp of Momordica charantia with insulin secretagogue and insulinomimetic activities. Biol Pharm Bull 29(6), 1126-1131.
7. Miura T, Itoh Y, Iwamoto N, Kato M & Ishida T (2004) Suppressive activity of the fruit of Momordica charantia with exercise on blood glucose in type 2 diabetic mice. Biol Pharm Bull 27 2), 248-250.
8. Ali L, Khan AK, Mamun MI, Mosihuzzaman M, Nahar N, Nure-Alam M & Rokeya B (1993) Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 59(5), 408-412.
9. Ahmed I, Lakhani MS, Gillett M, John A & Raza H (2001) Hypotriglyceridemic and hypocholesterolemic effects of antidiabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 51(3), 155-161.
10. Miura T, Itoh C, Iwamoto N, Kato M, Kawai M, Park SR & Suzuki I (2001) Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr Sci Vitaminol (Tokyo) 47(5), 340-344.
11. Roffey BW, Atwal AS, Johns T & Kubow S (2007) Water extracts from Momordica charantia increase glucose uptake and adiponectin secretion in 3T3-L1 adipose cells. J Ethnopharmacol 30, 77-84.
12. Storlien LH, James DE, Burleigh KM, Chisholm DJ & Kraegen EW (1986) Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J physiol 251, E576-E583.
13. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailey CJ & Bignell AHC (1981) Improvement in glucose tolerance due to Momordica charantia (karela). Brit Med J 282, 1823-1824.
14. Minsheng Y, Nicky K, Jongsoon L, Lone H, Zhi-Wei Li, Micheal K & Shoelson SE (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673-1677.
15. Youngren JF, John P & Barnard RJ (2001) Impaired insulin-receptor autophosphorylation is an early defect in fat-fed, insulin resistant rats. Am J Physiol 91, 2240-2247.
16. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF & Kohn CR (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90, 1839-1849.
17. Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantity of protein utilizing the principle of protein dye binding. Anal Biochem 72, 248-254.
18. Laemmli UK (1970) Cleavage of structural proteins during the assembly of head of bacteriophage T4. Nature, 227, 680-685.
19. Hansen PA, Han DH, Marshall BA, Nolte LA, Chen MM, Mueckler M & Holloszy JO (1998) A high fat diet impairs insulin stimulation of glucose transport in muscle. J Biol chem 273, 26157-26163.
20. Barnard RJ, Berger JJ, Ong JM & Kern PA (1998) Adipocyte and muscle changes in response to diet leading to obesity. Diabetes 33, 213-228.
21. Barnard RJ, Roberts CK, Varon SM & Berger JJ (1998) Diet induced insulin resistance precedes other aspects of metabolic syndrome. J Appl physiol 84, 1311-1315.
22. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ & Kraegen EW (1997) Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 46, 1768-1774.
23. White MF (1998) The IRS-signaling system: A network of docking protein that mediate insulin and cytokine action. Recent Prog Horm Res 53, 119-138.
24. Tamemoto H, Kadowaki T, Tobe K, et al. (1994) Insulin resistance and growth retardation in mice lacking inzulin receptor substrate-1. Nature 372, 182-186.
25. Yamauchi T, Tobe K, Tamemoto H, et al. (1996) Insulin signalling and insulin actions in the muscles and livers of insulin resistant, insulin receptor substrate 1- deficient mice. Mol Cell Biol 16 3074-3084.
26. Tanti JF, Gremeaux T, Van Obberghen E, et al. (1994) Serine/ threonine phosphorylation of insulin receptor substrate 1 modulates insulin signalling. J Biol Chem 269, 6051-6057.
27. De Fea K & Roth RA (1997) Modulation of insulin receptor substrate -1 tyrosine phosphorylation and function by mitogen activated protein kinase. J Biol Chem 272, 31400-31406.
28. Grover JK & Yadav SP (2004) Pharmacological actions and uses of Momordica charantia: A review. J Ethanopharmacol 93(1), 123-132.
29. Xiang L, Huang X, Chen L, Rao P & Ke L (2007) The reparative effects of Momordica Charantia Linn. extract on HIT-T15 pancreatic beta-cells. Asia Pac J Clin Nutr 16(1), 249-252.
30. Chuang CY, Hsu C, Chao CY, Wein YS, Kuo YH & Huang CJ (2006) Fractionation and identification of 9c, 11t, 13t-conjugated linolenic acid as an activator of PPAR alpha in bitter gourd (Momordica charantia L.). J Biomed Sci 13(6), 763-772.
31. Chao CY & Huang CJ (2003) Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J Biomed Sci 10(2), 782-791.
32. Beatrice D & Walter W (1999) Peroxisome proliferator - activated receptors: Nuclear control of metabolism. Endocrine Reviews 20 5), 649-688.
33. Kersten S, Desvergne B & Wahli W (2000) Roles of PPARs in health and disease. Diabetes 405, 421-424.
34. Spiegelmen BM (1997) PPAR-γ: Adipogenic regulator and thiazolidinedione receptor. Diabetes 47, 507-514.
35. Ji Ming Ye, Patric JD, Miguel A, et al. (2001) Peroxisome proliferator-activated receptor (PPAR) - α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats. Comparison with PPAR-γ activation. Diabetes 50, 411-417.
36. Forman BM, Chen J & Evans RM (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 94, 4312-4317.
37. Guerre-Millo M, Gervois P, Raspe E, et al. (2000) Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275, 16638-16642.
38. Werner DE, Lee J, Hansen L, Yuan M & Shoelson SE (2004) Insulin resistance due to phosphorylation of insulin receptor substrate-1 at serine 302. J Biol Chem 279, 35298-35305.
39. Kim JK, Kim YJ, Fillmore JJ et al. (2001) Prevention of fat induced insulin resistance by salicylate. J clin Invest 108, 437-448.
40. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H & Zick Y (1997) A molecular basis for insulin resistance: Elevated serine/ threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impair their ability to under go insulin stimulated tyrosine phosphorylation. J Biol Chem 272, 29911-29918.
41. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M & Shoelson SE (2001) Reversal of obesity and diet induced insulin resistance with salicylates or targeted disruption of IKKβ. Science 293, 1673-1677.
42. Sykiotis GP & Papavassiliou AG (2001) Serine phosphorylation of insulin receptor substrate-1: A novel target for the reversal of insulin resistance. Molecular Endocrinology 15, 1864-1869.